Coulter Partners conducts successful Chair search for Coramaze Technologies
London, May 7, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with MTIP and Coramaze Technologies (Coramaze) and is pleased to announce the placement of Rob ten Hoedt as Chair of Coramaze’s Board of Directors.
Coramaze Technologies is a pre-commercial medical technology company, focused on developing a novel tricuspid valve repair system, called Tripair™, a minimally invasive solution for treating tricuspid regurgitation (TR). Tripair™ simplifies TR repair through an innovative transcatheter edge-to-spacer approach, aiming to reduce procedural complexity and improve access to care.
MTIP, a Swiss-based growth equity and buyout firm, has been a committed partner to Coramaze since 2017, supporting its journey from early innovation to a breakthrough in tricuspid regurgitation treatment.
Rob ten Hoedt, a respected leader in the medical technology industry, joins Coramaze with a proven track record, including his roles as Executive Vice-President and President of Global Regions at Medtronic and Chair of MedTech Europe. He currently serves as Chair of the Board at ONWARD Medical.
A former Executive Committee Member at Medtronic, Ten Hoedt brings extensive global experience in medical technology innovation and strategic business growth. This expertise will be invaluable as Coramaze advances its groundbreaking Tripair Technology. His guidance will be crucial in navigating the transition from global feasibility studies to pivotal clinical trials, and ultimately, the commercialization and global market entry of Tripair.
“We are honored to welcome Rob as our Chair,” commented Jochen Reinöhl, CEO of Coramaze Technologies. “His strategic insights, deep industry expertise, and track record in building and scaling transformative technologies align perfectly with our mission. Rob’s appointment marks a significant milestone for Coramaze and reinforces the promise of Tripair™ as a game-changing therapy for tricuspid regurgitation.”
Jochen Reinöhl continued, “Rob’s appointment concludes a rigorous executive search process that MTIP initiated in collaboration with Coulter Partners. Their deep understanding of the transatlantic talent pool, coupled with their extensive personal connections, proved invaluable in our search for a new Chair. Their ability to leverage their network and foster a close relationship with both our investors and our company – building on my previous placement as CEO – demonstrated a level of partnership we truly appreciate. We look forward to continuing this fruitful collaboration.”
—-
Rob ten Hoedt, Chair of Board of Directors at Coramaze Technologies
Rob ten Hoedt’s extensive career in Medtech includes serving as Executive Vice President & President at Medtronic until August 2024, where he oversaw commercial operations in EMEA, Asia-Pacific, the USA, Canada and Latin America. He was a member of Medtronic’s Executive Committee and chaired the Board of MedTech Europe from 2014 to 2022. Joining Medtronic in 1991, he progressed through various regional and business leadership roles, including Executive Vice President & President, EMEA (later expanded to include APAC). Prior to Medtronic, Rob worked in several medical technology companies including Arjo Hospital Equipment and Polystan Benelux and also ran his own medical equipment distribution company. Rob graduated with a degree in Commercial Economy from the H.E.A.O., the Netherlands, and holds a Master’s in Marketing from the NIMA Business School.
[ENDS]
Notes to editors:
About Coramaze Technologies
Coramaze Technologies develops an innovative, highly differentiated, transcatheter tricuspid valve repair system, called Tripair™, a minimally invasive solution for treating tricuspid regurgitation. Using a novel edge-to-spacer design, Tripair™ enables tricuspid valve repair via a simple transcatheter procedure. The device is anchored atraumatically in the right atrium, is agnostic of valve morphology and can be retrieved if necessary —minimizing patient trauma and reducing procedural complexity.
Headquartered in Germany with a dedicated R&D center in Israel, Coramaze is a pre-commercial stage company. Following a successful first-in-human trial, Tripair™ is now being prepared for evaluation in global feasibility studies across multiple continents.
To learn more about Coramaze and its Tripair™ technology, visit www.Tripairtechnology.com
Note: Tripair™ is an investigational device and is not yet available for commercial use.
About MTIP
MTIP is a Swiss-based growth equity and buyout firm specializing in investments in European healthcare software companies. Our strategy focuses on partnering with high-growth, profitable businesses and visionary management teams. Leveraging our deep sector expertise, we help scale successful healthcare software companies achieve their full potential. At MTIP, our purpose is clear: Unlocking value, improving lives: Together with our portfolio companies, we create sustainable growth, advance innovation, and deliver long-term value that reshapes the global healthcare landscape.
For more information, visit www.mtip.ch
About Coulter Partners
We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.
